Hisham Bin Saad Al-Jadhey – CEO, Saudi Food and Drug Authority (SFDA)

22.03.2021
Speaking exclusively to PharmaBoardroom, Prof. Hisham Bin Saad Al-Jadhey, CEO of the Saudi Food and Drug Authority (SFDA), outlines the SFDA's key priorities under its current strategic plan. He also touches on why domestic pharma and medtech manufacturing is important to the SFDA, pricing issues for innovative new therapies, and the role of the Authority within the Saudi 'Vision 2030' plan.  
SFDA has been developing very fast over the past couple of years and our future is even more promising. We are improving our regulations and processes to protect our citizens and to bring more investments to Saudi Arabia
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
Saudi Arabia, SFDA, Regulator, Regulation, Halal Medicine, MEA, MENA

Related Interviews

Mohamed Mostafa – Vice President and General Manager Saudi Arabia &…

IQVIA Vice President and General Manager Saudi Arabia & Egypt Mohamed Mostafa gives his expert insights into the transformation of the Saudi pharma market in recent years, covering everything from…

Rami Rajab – Chairman, Mecomed

Mecomed is the largest medical devices, imaging, and diagnostics trade association in the Middle East and Africa (MEA). Rami Rajab, chairman, highlights the role of the association in shaping the…

Mohamed Mazen Batterjee – Managing Director, Batterjee Pharma

Mohamed Mazen Batterjee, managing director of Batterjee Pharma, explains how he has turned the business around since joining in 2014, the interplay between the firm’s contract and proprietary manufacturing operations,…

Related Articles

Company Spotlight / Saudi Chemical Company Holding: At the Forefront of Saudi Healthcare’s Evolution

Saudi Chemical Company Holding (SCCH), Saudi Arabia’s leading manufacturer of civil and military explosives, has been expanding its pharma sector footprint in recent years. Today, the company has capabilities across…

Pharma Faces / Mohammed Nasser, Amgen MEA

Seasoned executive Mohamed Nasser currently oversees 16 markets for Amgen across the MEA region, including its most important – Saudi Arabia. He shares some of the key skills that pharma…

Saudi Arabia / IP: Room for Improvement?

While Saudi Arabia is becoming an increasingly attractive investment destination for global pharma, some stakeholders continue to have concerns about whether the country’s intellectual property (IP) protection system is truly…

Latest Report

Saudi Arabia Pharma Report 2022

Related Content

Saudi Arabia
SFDA
Regulator
Regulation
Halal Medicine
MEA
MENA